

Data Sharing Statement

Hager KJ, Pérez Marc G, Gobeil P, et al. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med. DOI: 10.1056/NEJMoa2201300.

| Question | Authors' Response |
|---|---|
| Will the data collected for your study be made available to others? | Yes |
| Would you like to offer context for your decision? | — |
| Which data? | Other (e.g., partial data sets) |
| Additional information about data | Clinical data that support the findings of this study are available with permission of Medicago from the corresponding author (Brian J. Ward) or through communications@medicago.com upon reasonable request. To protect the privacy of patients and individuals involved in our studies, Medicago does not publicly disclose patient-level data. |
| How or where can the data be obtained? | Available with permission of Medicago from the corresponding author (wardb@medicago.com) or through communications@medicago.com. |
| When will data availability begin? | With publication |
| When will data availability end? | — |
| Will any supporting documents be available? | — |
| Which supporting documents? | — |
| Additional information about supporting documents | — |
| How or where can supporting documents be obtained? | — |
| When will supporting documents availability begin? | — |
| When will supporting documents availability end? | — |
| To whom will data be available? | — |
| For what type of analysis or purpose? | — |
| By what mechanism? | — |
| Any other restrictions? | — |
| Additional information | — |

This statement was posted on May 4, 2022, at [NEJM.org](https://www.nejm.org).